GVHD

Jul 04, 2025

The GvHD drugs treatment landscape is undergoing a dynamic transformation, driven by a wave of innovation aimed at improving patient outcomes and quality of life. Once dominated by steroids and broad immunosuppressants, the field is now witnessing a surge in targeted therapies, cellular approaches, and novel biolog...

Jun 23, 2023

Allogeneic HSCT is a mainstay for patients with different hematological malignancies, but it requires immunosuppressive strategies before and after HSCT. However, approximately half (50%) of the patients receiving allogeneic hematopoietic stem cell transplantation (HCT) from a human leukocyte antigen (HLA)-matched ...

May 10, 2022

AstraZeneca’s Farxiga Meets Primary Endpoints in Phase 3 Heart Failure Trial Farxiga, an SGLT2 inhibitor from AstraZeneca, has shown positive results in a phase 3 Heart Failure trial, putting it back in contention with Jardiance from Boehringer Ingelheim and Eli Lilly. The DELIVER trial's top-line results demons...

Oct 18, 2019

Incyte Corporation has recently announced the results of Novartis-sponsored Phase III clinical trials REACH2 evaluating its candidate Ruxolitinib (Jakafi) in patients suffering from steroid-refractory acute graft-versus-host disease (GvHD). Graft versus host disease (GvHD), as defined by the National Cancer Institu...

Sep 19, 2019

FUJIFILM Corporation has signed an exclusive licensing agreement with an Australian bio-venture Cynata Therapeutics Limited for CYP-001. Under the agreement, FUJIFILM will gain rights to develop, manufacture and market a drug for the treatment of graft-versus-host disease (GvHD). CYP-001 is a Cynata’s lead cand...

Sep 11, 2019

Regenerative medicine is an innovative approach to regrow and repair the damaged cells, tissues or organs. The process involves the regeneration of the lost body cells by stimulating the body’s own immune system. Regenerative medicine includes a group of biomedically engineered approaches that uses therapeutic stem...